These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 33414418)
1. Towards in vivo imaging of functionally active 5-HT Razakarivony O; Newman-Tancredi A; Zimmer L Transl Psychiatry; 2021 Jan; 11(1):22. PubMed ID: 33414418 [TBL] [Abstract][Full Text] [Related]
10. PET radiotracers for molecular imaging of serotonin 5-HT1A receptors. Billard T; Le Bars D; Zimmer L Curr Med Chem; 2014; 21(1):70-81. PubMed ID: 23992341 [TBL] [Abstract][Full Text] [Related]
11. In vivo biased agonism at 5-HT Vidal B; Fieux S; Redouté J; Villien M; Bonnefoi F; Le Bars D; Newman-Tancredi A; Costes N; Zimmer L Neuropsychopharmacology; 2018 Oct; 43(11):2310-2319. PubMed ID: 30030540 [TBL] [Abstract][Full Text] [Related]
12. Dopamine D2 and serotonin 5-HT1A receptor interaction in the context of the effects of antipsychotics - in vitro studies. Łukasiewicz S; Błasiak E; Szafran-Pilch K; Dziedzicka-Wasylewska M J Neurochem; 2016 May; 137(4):549-60. PubMed ID: 26876117 [TBL] [Abstract][Full Text] [Related]
14. Serotonin 5-HT1A Receptors and Antipsychotics - An Update in Light of New Concepts and Drugs. McCreary AC; Newman-Tancredi A Curr Pharm Des; 2015; 21(26):3725-31. PubMed ID: 26044980 [TBL] [Abstract][Full Text] [Related]
15. Actions of novel antipsychotic agents on apomorphine-induced PPI disruption: influence of combined serotonin 5-HT1A receptor activation and dopamine D2 receptor blockade. Auclair AL; Kleven MS; Besnard J; Depoortère R; Newman-Tancredi A Neuropsychopharmacology; 2006 Sep; 31(9):1900-9. PubMed ID: 16421514 [TBL] [Abstract][Full Text] [Related]
16. [carbonyl-11C]Desmethyl-WAY-100635 (DWAY) is a potent and selective radioligand for central 5-HT1A receptors in vitro and in vivo. Pike VW; Halldin C; McCarron JA; Lundkvist C; Hirani E; Olsson H; Hume SP; Karlsson P; Osman S; Swahn CG; Hall H; Wikström H; Mensonidas M; Poole KG; Farde L Eur J Nucl Med; 1998 Apr; 25(4):338-46. PubMed ID: 9553162 [TBL] [Abstract][Full Text] [Related]
17. Synthesis, in vitro and in vivo evaluation of Narayanaswami V; Tong J; Fiorino F; Severino B; Sparaco R; Magli E; Giordano F; Bloomfield PM; Prabhakaran J; Mann JJ; Vasdev N; Dahl K; Kumar JSD EJNMMI Radiopharm Chem; 2020 May; 5(1):13. PubMed ID: 32430632 [TBL] [Abstract][Full Text] [Related]
18. A positron emission tomography study of the 5-HT1A receptor in schizophrenia and during clozapine treatment. Bantick RA; Montgomery AJ; Bench CJ; Choudhry T; Malek N; McKenna PJ; Quested DJ; Deakin JF; Grasby PM J Psychopharmacol; 2004 Sep; 18(3):346-54. PubMed ID: 15358978 [TBL] [Abstract][Full Text] [Related]
19. Pharmacological MRI to investigate the functional selectivity of 5-HT Vidal B; Bolbos R; Redouté J; Langlois JB; Costes N; Newman-Tancredi A; Zimmer L Neuropharmacology; 2020 Aug; 172():107867. PubMed ID: 31783063 [TBL] [Abstract][Full Text] [Related]
20. Dual ligands targeting dopamine D2 and serotonin 5-HT1A receptors as new antipsychotical or anti-Parkinsonian agents. Ye N; Song Z; Zhang A Curr Med Chem; 2014; 21(4):437-57. PubMed ID: 24164194 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]